Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JB-132
- Development stage
- Preclinical
- Lead developer
- Junten Bio
01
Overview
JB-132 is a preclinical drug candidate being developed by Junten Bio, a biotechnology company focused on establishing immune tolerance in organ transplantation. The drug is part of a pipeline aimed at preventing graft rejection and reducing the dependency on long-term immunosuppressive medications. While specific details regarding its modality and molecular targets are not yet publicly available, Junten Bio's platform primarily utilizes inducible inhibitory T-cells and specialized antibody drugs to modulate the immune response in transplant recipients. JB-132 is currently being investigated for its potential application in organ transplantation and may eventually be explored for other intractable diseases caused by hyperimmune reactions.
Beyond the preview
Go deeper on JB-132.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JB-132.